Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-free survival ...

Roche ( OTCQX:RHHBY) ( OTCQX:RHHBF) ( OTCPK:RHHVF) said that the European Commission has approved its oral cancer drug, ...

Basel: Roche has received approval from the European Commission for Itovebi (inavolisib), in combination with palbociclib ...

The European Commission has approved Swiss pharma giant Roche’s Itovebi (inavolisib), in combination with palbociclib ...

Itovebi-based regimen significantly improved OS and PFS in PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients. The FDA approved the Itovebi-based combination in October 2024 for ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Itovebi ...

Itovebi, Ibrance, and Faslodex significantly improved OS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer compared to placebo. The INAVO120 trial showed a median OS of 34.0 months ...

Itovebi is an oral, targeted treatment with best-in-class potential that could provide well-tolerated, durable disease control and potentially improved outcomes for people with PIK3CA-mutated, hormone ...

Genentech Therapeutics’s Phase III trial of Itovebi in patients with certain types of metastatic breast cancer has met the gold standard oncology endpoint of overall survival (OS) while also ...

Itovebi is supplied as a tablet in 2 dosage strengths: 3 mg and 9 mg. Patients should be selected for treatment based on the presence of 1 or more PIK3CA mutations in plasma specimens.

Genentech, a member of the Roche Group, announced today positive topline results from the overall survival analysis of the Phase III INAVO120 study investigating Itovebi TM in combination with ...

Roche’s Itovebi gets European approval to treat people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation: Basel Thursday, July 24, 2025, 09:00 Hrs [ ...